![](/img/cover-not-exists.png)
P118 Preliminary results of HOPLITE trial, a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC)
Caffo, O., Lo Re, G., Sava, T., Buti, S., Sacco, C., Basso, U., Zustovich, F., Martini, T., Perin, A., Veccia, A., Russo, L.M., Facchini, G., Barile, C., Gernone, A., De Vivo, R., Pappagallo, G., GallVolume:
11
Language:
english
Journal:
European Urology Supplements
DOI:
10.1016/S1569-9056(13)60484-4
Date:
November, 2012
File:
PDF, 72 KB
english, 2012